Potential Diagnostic and Prognostic Value of Plasma Circulating MicroRNA-182 in Human Glioma

Overview

Journal Med Sci Monit

Specialties General Medicine
Pathology

Date 2016 Mar 16

PMID 26978735

Citations 33

Authors

Yilei Xiao

Lina Zhang

Zikun Song

Chuanjun Guo

Jianxin Zhu

Zhongmin Li

Shugan Zhu

Affiliations

Soon will be listed here.

Abstract

Background: Previous studies showed the aberrant expression of microRNA-182 (miR-182) in glioma tissue. However, the exact role of circulating miR-182 in glioma remains unclear. Here, we confirmed the expression of plasma circulating miR-182 in glioma patients, and further explored its potential diagnostic and prognostic value.

Material/methods: Real-time quantitative PCR (RT-PCR) was used to measure circulating cell-free miR-182 from 112 glioma patients and 54 healthy controls.

Results: Our findings showed that the level of circulating miR-182 in glioma patients was higher than that in healthy controls (P<0.001), which was significantly associated with KPS score (P=0.025) and WHO grade (P<0.001). The area under the receiver operating characteristic (ROC) curve (AUC) was 0.778. The optimal cut-off value was 1.56, and the sensitivity and specificity were 58.5% and 85.2%, respectively. Interestingly, a high predictive value of circulating miR-182 was observed in high-grade glioma (AUC=0.815). However, the AUC was lower in low-grade glioma (AUC=0.621). Kaplan-Meier analysis demonstrated that the cumulative 5-year overall survival rate in the high miR-182 group was significantly lower than that in the low miR-182 group in both overall survival (OS) (P=0.003) and disease-free survival (DFS) (P=0.006). Moreover, multivariate Cox analysis revealed that circulating miR-182 was an independent prognostic indicator for OS (P=0.034) and DFS (P=0.013).

Conclusions: These results suggest that circulating miR-182 may be a potential noninvasive biomarker for the diagnosis and prognosis of human glioma.

Citing Articles

Unlocking the Potential of Circulating miRNAs as Biomarkers in Glioblastoma.

Suvarnapathaki S, Serrano-Farias A, Dudley J, Bettegowda C, Rincon-Torroella J Life (Basel). 2024; 14(10).

PMID: 39459612 PMC: 11509808. DOI: 10.3390/life14101312.

Circulating Liquid Biopsy Biomarkers in Glioblastoma: Advances and Challenges.

Seyhan A Int J Mol Sci. 2024; 25(14).

PMID: 39063215 PMC: 11277426. DOI: 10.3390/ijms25147974.

Prospective Prediction of Treatment Response in High-Grade Glioma Patients using Pre-Treatment Tumor ADC Value and miR-222 and miR-205 Expression Levels in Plasma.

Heidari M, Amouheidari A, Hemati S, Khanahmad H, Rahimmanesh I, Jafari P J Biomed Phys Eng. 2024; 14(2):111-118.

PMID: 38628894 PMC: 11016827. DOI: 10.31661/jbpe.v0i0.2108-1376.

MicroRNA as a potential diagnostic and prognostic biomarker in brain gliomas: a systematic review and meta-analysis.

Hasani F, Masrour M, Jazi K, Ahmadi P, Hosseini S, Lu V Front Neurol. 2024; 15:1357321.

PMID: 38487328 PMC: 10937740. DOI: 10.3389/fneur.2024.1357321.

MicroRNA signatures differentiate types, grades, and stages of breast invasive ductal carcinoma (IDC): miRNA-target interacting signaling pathways.

Verma V, Beevi S, Nair R, Kumar A, Kiran R, Alexander L Cell Commun Signal. 2024; 22(1):100.

PMID: 38326829 PMC: 10851529. DOI: 10.1186/s12964-023-01452-2.

References

He L, Hannon G . MicroRNAs: small RNAs with a big role in gene regulation. Nat Rev Genet. 2004; 5(7):522-31. DOI: 10.1038/nrg1379. View

Chu S, Ma Y, Feng D, Zhang H, Zhu Z, Li Z . Correlation of low SLC22A18 expression with poor prognosis in patients with glioma. J Clin Neurosci. 2011; 19(1):95-8. DOI: 10.1016/j.jocn.2011.04.032. View

Hui A, Lin A, Xu W, Waldron L, Perez-Ordonez B, Weinreb I . Potentially prognostic miRNAs in HPV-associated oropharyngeal carcinoma. Clin Cancer Res. 2013; 19(8):2154-62. DOI: 10.1158/1078-0432.CCR-12-3572. View

Ng E, Li R, Shin V, Jin H, Leung C, Ma E . Circulating microRNAs as specific biomarkers for breast cancer detection. PLoS One. 2013; 8(1):e53141. PMC: 3536802. DOI: 10.1371/journal.pone.0053141. View

Livak K, Schmittgen T . Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2002; 25(4):402-8. DOI: 10.1006/meth.2001.1262. View

Chen X, Ba Y, Ma L, Cai X, Yin Y, Wang K . Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res. 2008; 18(10):997-1006. DOI: 10.1038/cr.2008.282. View

Yu S, Liu Y, Wang J, Guo Z, Zhang Q, Yu F . Circulating microRNA profiles as potential biomarkers for diagnosis of papillary thyroid carcinoma. J Clin Endocrinol Metab. 2012; 97(6):2084-92. DOI: 10.1210/jc.2011-3059. View

Zheng D, Haddadin S, Wang Y, Gu L, Perry M, Freter C . Plasma microRNAs as novel biomarkers for early detection of lung cancer. Int J Clin Exp Pathol. 2011; 4(6):575-86. PMC: 3160609. View

Selth L, Townley S, Bert A, Stricker P, Sutherland P, Horvath L . Circulating microRNAs predict biochemical recurrence in prostate cancer patients. Br J Cancer. 2013; 109(3):641-50. PMC: 3738112. DOI: 10.1038/bjc.2013.369. View

10.

Du W, Pang C, Wang D, Zhang Q, Xue Y, Jiao H . Decreased FOXD3 Expression Is Associated with Poor Prognosis in Patients with High-Grade Gliomas. PLoS One. 2015; 10(5):e0127976. PMC: 4444112. DOI: 10.1371/journal.pone.0127976. View

11.

Hutterer M, Hattingen E, Palm C, Proescholdt M, Hau P . Current standards and new concepts in MRI and PET response assessment of antiangiogenic therapies in high-grade glioma patients. Neuro Oncol. 2014; 17(6):784-800. PMC: 4483117. DOI: 10.1093/neuonc/nou322. View

12.

Qu Y, Li W, Hellem M, Rostad K, Popa M, McCormack E . MiR-182 and miR-203 induce mesenchymal to epithelial transition and self-sufficiency of growth signals via repressing SNAI2 in prostate cells. Int J Cancer. 2013; 133(3):544-55. DOI: 10.1002/ijc.28056. View

13.

Scheffer A, Holdenrieder S, Kristiansen G, von Ruecker A, Muller S, Ellinger J . Circulating microRNAs in serum: novel biomarkers for patients with bladder cancer?. World J Urol. 2012; 32(2):353-8. DOI: 10.1007/s00345-012-1010-2. View

14.

Yue X, Lan F, Hu M, Pan Q, Wang Q, Wang J . Downregulation of serum microRNA-205 as a potential diagnostic and prognostic biomarker for human glioma. J Neurosurg. 2015; 124(1):122-8. DOI: 10.3171/2015.1.JNS141577. View

15.

Hanke M, Hoefig K, Merz H, Feller A, Kausch I, Jocham D . A robust methodology to study urine microRNA as tumor marker: microRNA-126 and microRNA-182 are related to urinary bladder cancer. Urol Oncol. 2009; 28(6):655-61. DOI: 10.1016/j.urolonc.2009.01.027. View

16.

Lei R, Tang J, Zhuang X, Deng R, Li G, Yu J . Suppression of MIM by microRNA-182 activates RhoA and promotes breast cancer metastasis. Oncogene. 2013; 33(10):1287-96. DOI: 10.1038/onc.2013.65. View

17.

Wang P, Gong H, Li B, Lv C, Wang H, Zhou H . Higher expression of circulating miR-182 as a novel biomarker for breast cancer. Oncol Lett. 2013; 6(6):1681-1686. PMC: 3834356. DOI: 10.3892/ol.2013.1593. View

18.

McDermott A, Miller N, Wall D, Martyn L, Ball G, Sweeney K . Identification and validation of oncologic miRNA biomarkers for luminal A-like breast cancer. PLoS One. 2014; 9(1):e87032. PMC: 3909065. DOI: 10.1371/journal.pone.0087032. View

19.

Louis D, Ohgaki H, Wiestler O, Cavenee W, Burger P, Jouvet A . The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007; 114(2):97-109. PMC: 1929165. DOI: 10.1007/s00401-007-0243-4. View

20.

Zhu C, Ren C, Han J, Ding Y, Du J, Dai N . A five-microRNA panel in plasma was identified as potential biomarker for early detection of gastric cancer. Br J Cancer. 2014; 110(9):2291-9. PMC: 4007222. DOI: 10.1038/bjc.2014.119. View